GENITOURINARY CANCERS
Latest News
October 10th 2024
According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall survival vs enzalutamide monotherapy.
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
More News
Cabozantinib (Cometriq) Improves PFS and OS in Patients With mRCC
July 20th 2015Results from the phase III METEOR study showed that treatment with cabozantinib (Cometriq) improved progression-free survival (PFS) and overall survival (OS) compared with everolimus (Afinitor) in previously treated patients with metastatic renal cell carcinoma (mRCC).
Read More
Efficacy of Blinatumomab Presented in Phase II Ph+ ALL Study
July 20th 2015According to findings from a phase II study released by Amgen, monotherapy with blinatumomab (Blincyto) showed promising complete remission (CR) or CR with partial hematological recovery (CRh) rates in adult patients with relapsed or refractory Philadelphia chromosome-positive (Ph+) B cell precursor acute lymphoblastic leukemia (ALL).
Read More
Baseline Analysis of CTC Enumeration and AR Localization in Men With mCRPC
July 7th 2015Scott T. Tagawa, MD, MS, medical director, Genitourinary Oncology Research Program, associate professor, Clinical Medicine and Urology, Weill Cornell Medical College, discusses the baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC).
Watch
